You are here

Agilent (US) acquires biotech firm Multiplicom (Flanders)

US-based scientific measuring instruments expert Agilent Technologies is acquiring Multiplicom – a biotechnology company in the town of Niels, near Antwerp, Flanders. The acquisition is expected to be finalized by mid-January, and totals an investment of EUR 68 million.

Genomics galore

Multiplicom specializes in technology for genetic tests, and develops, produces and commercializes molecular-diagnostic kits that enable personalized healthcare. “By acquiring Multiplicom, we strengthen our position on the genomics market,” explains Herman Verrelst, vice president and general manager of Agilent’s Genomics Division. “Multiplicom’s products and technology broadens and enriches our portfolio, creating a lot of potential in Flanders’ neighboring markets.”

Bigger market

“We look forward to becoming part of Agilent,” comments Dirk Pollet, CEO of Multiplicom. “The acquisition gives us the opportunity to offer our products and technology to a much bigger market. Yet, we would also like to thank our initial investors – Gimv, PMV, Qbic, RMM, Antwerp University and Flanders’ institute for biotechnology VIB – for their support from day one.”

More info

MultiplicomMore information about medical technology in Flanders
Reported by
16 January 2017

More news about Flanders?

  • Regular updates
  • No spam

Interested in doing business in Flanders?

Let us help you!

  • We can introduce you to other companies, banks and regulators
  • We organize site visits to real estate locations
  • We assist with all legal aspects of setting up a business
  • We're an official government agency
  • Our services are completely free
  • We are a team of international experts

Receive our handbook to growing your business in Flanders

  • It's completely free.
  • Get an overview of all incentives relevant to your company.
  • Tax system explained in-depth.
  • Learn how to set up your business quickly.
  • Discover the benefits of Flanders (in addition to the chocolate).

In addition to the ebook, I agree to receive one or two follow-up emails